Search PubMed⌕ Search

Biomedical subjects

R S Foster

Publications and source records attributed to R S Foster.

At least 127 records · Page 7Linked to original sources
PubMed1994

Splenic rupture during occlusion of the porta hepatis in resection of tumors with vena caval extension.

The surgical management of renal cell carcinoma with intraluminal extension into the vena cava is technically demanding. Although the curative merit of the procedure is well established, extension of tumor above the hepatic veins may cause potentially life threatening complications, including pulmonary embolus and exsanguination. To our knowledge we report the first 2 cases in which intraoperative splenic rupture occurred and discuss possible causes of this complication.

Constriction↗
PubMed1994

High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience.

High intensity focused ultrasound via a transrectal approach was used to treat 15 patients with symptomatic benign prostatic hyperplasia. The first 10 of these 15 patients underwent continuous temperature monitoring of the periprostatic region throughout the treatment. Patients undergoing transperineal thermocouple placement for the purpose of thermometry were treated while under general or spinal anesthesia, whereas 4 of the 5 remaining patients were successfully treated using intravenous sedation alone. Of the 10 patients 9 did not demonstrate a significant temperature elevation. One patient with a small prostatic anteroposterior diameter had a transient elevation of 17C. No patient experienced a complication related to periprostatic heating. Followup was available at 90 days in all patients. At 90 days the symptom scores decreased from a pretreatment value (American Urological Association questions 1 to 7) of 31.2 (range 22 to 38) to 15.8 (range 8 to 31). Peak flow rate increased by a mean of 4.7 ml per second from 9.3 ml per second before treatment to 14.0 ml per second at 90 days. The most frequent complication was that of transient urinary retention in 11 of 15 patients (73.3%) and hematospermia in 7 (46.7%). No adverse reactions persisted at 90 days. This study represents an initial attempt using high intensity focused ultrasound to treat symptomatic benign prostatic hyperplasia. Overall, the safety and effectiveness of high intensity focused ultrasound demonstrated in this pilot study are encouraging.

Aged↗
PubMed1994

The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis.

Sixty-nine cases of clinical Stage I non-seminomatous germ cell tumors (NSGCT) of the testis were immunostained for the protein product of the p53 tumor suppressor gene using a microwave-based antigen retrieval method. It was assumed that the immunohistochemical detection of the p53 protein corresponded to a point mutation in the p53 gene, the wild-type p53 protein turning over too rapidly to be detected by routine immunohistochemical techniques. The results of p53 staining were then compared with the results, on the same paraffin tissue blocks, of S-phase analysis, as determined by flow cytometry, and the percentage of neoplastic cells exhibiting immunohistochemical positivity for proliferating cell nuclear antigen (PCNA). Thirty-four of 69 (49%) of the clinical Stage I NSGCT exhibited p53-positivity as strong, but focal, intranuclear positivity. Both the mean total S-phase and the mean percentage of PCNA-positive neoplastic cells were significantly higher in the p53-positive cases (27.8% and 89.6%, respectively) compared with the p53-negative cases (17.6% and 66.1%, respectively). Stratification of cases into high (> or = 76%) and low categories for PCNA values correlated significantly (P < 0.0005) with p53-positivity and negativity, respectively, by chi 2 analysis. The positive association of p53 protein expression with higher proliferative indices in NSGCT of the testis is consistent with the observation of p53 mutations correlating with markers of increased tumor aggressiveness in other types of neoplasia.(ABSTRACT TRUNCATED AT 250 WORDS)

DNA, Neoplasm↗
PubMed1994

Management of retroperitoneal recurrences. Seminoma and nonseminoma.

Management of retroperitoneal recurrent tumor remains a great challenge. Accurate radiographic and clinical restaging and careful consultation with prior treating physicians can provide valuable insights into the history of each patient's disease. This, in turn, helps with choice of incision and exposure requirements. The surgeon must be prepared for all contingencies in the belly and chest, including vascular resections. When this is done, nearly 75% of patients can be rendered free of disease.

Antineoplastic Agents↗
PubMed1994

Complications of primary retroperitoneal lymph node dissection.

The surgical morbidity in 478 patients who underwent primary retroperitoneal lymphadenectomy for clinical stages I and II nonseminomatous testicular cancer from 1982 to 1992 was reviewed. There were 54 complications in 51 patients (10.6%) and no operative related mortality. Superficial wound infection was the most frequent complication, comprising 45% of the total number of complications. Most major complications were related to small bowel obstruction and atelectasis. No complications caused permanent disability. The complication rate was less in patients who underwent a modified unilateral procedure (9.4%) than in those who underwent bilateral dissection (19.3%). Complications were significantly less with procedures done during the latter 6 years of the study (1987 to 1992). The ejaculation rate of patients undergoing a nerve sparing procedure was 98%, which reflects the increase in experience gained with the technique of nerve sparing modified unilateral dissection for early stage testicular cancer. This study reinforces the view that primary retroperitoneal lymph node dissection is an operation with minimal morbidity and no long-term effects. Furthermore, this study serves as the basis for cost-benefit and risk-benefit analyses of primary retroperitoneal lymph node dissection in low stage testicular cancer, which can be set against surveillance and primary chemotherapy programs.

Humans↗
PubMed1994

Chyloperitoneum following treatment for advanced gynecologic malignancies.

BACKGROUND: Chyloperitoneum is an uncommon complication following retroperitoneal surgery. Blunt abdominal trauma, abdominal surgery, abdominal or pelvic radiation, cirrhosis, lymphoma, tuberculosis, and congenital defects of lacteal formation may also lead to chylous ascites. CASES: Two patients developed chylous ascites after treatment for gynecologic malignancies. One, who also received pelvic and abdominal radiation, developed chylous ascites 11 months after retroperitoneal lymph node dissection for advanced endometrial cancer. She was treated with a diet low in fat and high in medium-chain triglycerides, as well as with intravenous hyperalimentation. She had recurrences of chylous ascites, which responded to paracentesis and intravenous hyperalimentation. The second patient developed chylous ascites 2 months after retroperitoneal lymph node dissection for advanced fallopian tube cancer. She was treated with a medium-chain triglyceride diet, which resulted in resolution of her symptoms. CONCLUSION: Chyloperitoneum is an uncommon complication following treatment for gynecologic malignancies. Our second case is the first reported in which retroperitoneal lymph node dissection for gynecologic malignancy resulted in chyloperitoneum. However, because gynecologic malignancies frequently metastasize to the periaortic lymph nodes, chylous ascites may be an important cause of morbidity following treatment.

Adenocarcinoma↗
PubMed1994

Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary.

BACKGROUND: The growing teratoma syndrome has been described with regard to gonadal and extragonadal germ cell neoplasms in males, but few cases have been reported in the female population. In this condition, masses that enlarge during or after chemotherapy are found to contain mature teratoma without malignant elements. CASES: Three patients had either persistent or growing masses despite chemotherapy for germ cell malignancies of the ovary. All cases fit the description of the growing teratoma syndrome. The patients were aged 20-22 years. All three patients had immature teratomas before chemotherapy. The stages of disease ranged from Ia to IIIc. All patients had normal tumor markers while their masses showed growth or persistence. All were free of disease 6-31 months after diagnosis. CONCLUSION: Growth or persistence of a tumor after chemotherapy for malignant teratoma does not necessarily imply progression of malignancy, especially if tumor markers are normal. However, these masses should be resected because they may cause obstruction, compression, or displacement of adjacent organs, or undergo sarcomatous degeneration.

Adult↗
PubMed1993

Breast cancer and earlier detection efforts. Realized and unrealized impact on stage.

OBJECTIVE: To test our hypotheses that increased public and professional education in breast cancer detection (screening mammography, clinical breast examination, and breast self-examination) would lead to detection at earlier stages of disease with each of the three methods. DESIGN AND SETTING: A survey study of all pathologically diagnosed breast cancers in a defined geographic area (all nonfederal general hospitals in the state of Vermont) before (1975-1984, n = 1652) and after (1989-1990, n = 683) screening mammography became more commonly used. MAIN OUTCOME MEASURES: Method of detection of breast cancer and stage at detection. RESULTS: The age-adjusted annual incidence rate of breast cancer among adult women was 99 per 100,000 during the years 1975 to 1984 compared with 169 per 100,000 during 1989-1990 (P < .001). Mammography as the method of detection increased in use from 2% to 36% (P < .001). In the later era, invasive breast cancers were detected at more favorable TNM stage (P < .001); mean maximum tumor diameter was smaller (2.2 cm vs 2.7 cm; P < .001); percentage of histologically positive nodes was lower (37% vs 47%; P < .001). When mammographically detected cancers were excluded from the analysis of invasive cancers, the mean maximum tumor diameter and percentage of negative nodes in the two eras were similar even though there was an apparent shift to detection at an earlier clinical stage. CONCLUSION: The earlier stages of detection and the sudden increase in incidence could almost entirely be credited to screening mammography. Mammographic screening had a much greater impact on stage at detection in women aged 50 years and older than in those younger than 50 years.

Adult↗
PubMed1993

Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer.

Iatrogenic ascites is an uncommon complication of surgery of the retroperitoneum, the base of the mesentery or mediastinum. We treated 18 patients with chylous ascites occurring after retroperitoneal dissection for testicular cancer. Patients were diagnosed by paracentesis or on clinical grounds (increasing abdominal girth). Of interest, 6 patients underwent resection of the inferior vena cava as part of the procedure, and this appears to be a high risk group for this complication. Management options include dietary restriction of fat, administration of medium chain triglycerides and diuretics, hyperalimentation, peritoneovenous shunt or surgery. The majority of patients were managed successfully by dietary treatment.

Adolescent↗
PubMed1993

Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation.

Results with primary retroperitoneal lymphadenectomy in 464 patients with clinical stage A nonseminomatous germ cell testis cancer (1965 to 1989) were reviewed. The false-negative staging error by clinical methods remains at 30%. The relapse rate in pathological stage A cancer patients was 11% (37 of 323), with 2 deaths. For pathological stage B disease 64% of the patients were cured by retroperitoneal lymphadenectomy alone. With modern adjuvant chemotherapy no stage B tumor relapsed since 1979 and the survival rate was 100%. For all 25 years (464 patients) the relapse rate was 14% and the survival rate was 98.9% (3 cancer and 2 noncancer deaths). Because these results are based on preoperative clinical staging, they are directly comparable with series using radiotherapy or surveillance.

Adolescent↗
PubMed1993

Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989.

The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non-seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965-1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965-1978) and contemporary (1979-1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15% (n = 13) was similar to that of radiotherapy series but survival (97.7% after RPLND) was superior to that achieved with irradiation (87%). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30% of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12% and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34%. No relapse was seen among 48 pathological stage B patients who received post-operative adjuvant chemotherapy. The death rate was 0.8% among 378 clinical stage A RPLND patients. While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve-sparing techniques have been developed, the only long-term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve-sparing RPLND techniques in the management of clinical stage A disease.

Adolescent↗
PubMed1993

A preliminary report: postoperative fertility assessment in nerve-sparing RPLND patients.

Nerve-sparing RPLND is a procedure suited to patients with clinical stage I nonseminoma. Additionally, nerve-sparing techniques are applicable to patients with higher stage disease. Although ejaculation is reliably preserved with nerve-sparing techniques, the question of these patients' fertility has remained. Fertility was assessed in these patients by two techniques: laboratory analysis of semen and a post-RPLND questionnaire. Semen analyses and DNA histograms suggested fertility in > 70%; in addition, 43 of 53 (81%) patients who have tried to father children post RPLND have been successful. Nerve-sparing RPLND appears to be able to preserve fertility potential in these patients.

DNA, Neoplasm↗
PubMed1993

Production of prostatic lesions in canines using transrectally administered high-intensity focused ultrasound.

High-intensity focused ultrasound is a method of destroying tissue at a point distant from the transducer without injuring intervening tissue. A transrectal probe was developed and used to treat 26 canines in order to determine the feasibility of using this therapy in humans. Lesions of coagulative necrosis which evolved into cystic cavities were produced. Surrounding tissue was preserved without evidence of injury.

Animals↗
PubMed1993

High-intensity focused ultrasound in the treatment of prostatic disease.

Beginning in 1987, high-intensity focused ultrasound was investigated experimentally in a canine model to determine whether or not prostate tissue could be destroyed with good aiming and control. Subsequently a transrectal probe was developed and used to treat canine prostates in a formal study to determine whether or not this technology could be used to treat human benign prostatic hypertrophy. Next, after FDA approval, 15 patients were treated at Indiana University in the fall of 1992. Both canine and human studies have shown that high-intensity focused ultrasound administered via a transrectal probe is capable of creating prostate lesions without injury to intervening and surrounding tissue.

Animals↗